Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.53 |
| ▸ | DRD3 | P35462 | 8/20 | 0.53 |
| ▸ | DRD1 | P21728 | 5/20 | 0.53 |
| ▸ | DRD4 | P21917 | 5/20 | 0.53 |
| ▸ | DRD5 | P21918 | 5/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23364621 | 0.82 | DRD2 (0.54) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL29932780 | 0.81 | KDM1A (0.44) | FFAR1 | |
| SCHEMBL23364785 | 0.81 | KDM1A (0.44) | FFAR1 | |
| SCHEMBL10180323 | 0.77 | DRD2 (0.65) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL29932789 | 0.76 | OPRL1 (0.46) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL23364743 | 0.76 | OPRL1 (0.46) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL10180668 | 0.76 | DRD2 (0.63) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL10295472 | 0.75 | DRD2 (0.59) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL12314080 | 0.75 | DRD2 (0.59) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL4828687 | 0.74 | DRD2 (0.67) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | DRD2 4297/4885DRD3 4437/4885DRD1 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.